Magellan Health Insights
  • Home
  • About
  • Resources
  • Voices
  • Contact

Stuck between a Rock and an Empty Insulin Vial

by Lara Frick July 18, 2019Diabetes, Magellan Health, Pharmacy, Pharmacy Benefits Management, Trend Alert

While there may be some debate as to who deserves credit for originally developing insulin in the 1920s, there is no doubt that its serendipitous discovery had a life-saving impact. In an attempt to provide affordable treatment to the public, the researchers opted to sell the patent for insulin to the University of Toronto for $1. The researchers later collaborated with a pharmaceutical company to develop insulin due to limited ability of the university to develop it on its own. Once made primarily from animal sources in limited selection, several insulin options are now available, and each product differs slightly in manufacturing and design to better mimic the lacking endogenous insulin in patients with diabetes. Today, insulin is marketed primarily by three manufacturers, and counterintuitive to its length of time on the market as a primary treatment, insulin costs continue to increase. One assessment reported that annual spending per person with type 1 diabetes nearly doubled between 2012 and 2016, and the reported cost of one specific brand of insulin increased by 668% from 2001 to 2015. There are several purported reasons for the high costs of insulin, even resulting in lawsuits and a push for legislative involvement.

The high cost of insulin is a hurdle for many patients and the entire healthcare system, especially considering a reported 1.2 million Americans have type 1 diabetes and a portion of the nearly 30 million Americans with type 2 diabetes are insulin-dependent. So, what happens when a medication necessary for life continues to increase in price? Patients may resort to acquiring insulin from less expensive resources outside of the United States (US). In addition, some patients will continue to use insulin vials beyond their stable use (i.e., beyond 28 days once opened) or share insulin pens. Patients may ration their insulin for their own use or sell the remaining insulin to others, as the temptation for potential income may be too enticing for those with limited financial means. One study reported that the rise in costs has resulted in nearly 25% of patients not taking insulin as directed. Lack of blood glucose control resulting from these measures could be life-threatening.

Taking insulin access to another level, one project aims to develop a protocol for insulin production that would circumvent intellectual property concerns, enabling manufacturers to produce more affordable insulin. Theoretically, an open protocol for manufacturing of insulin could result in community biolab production or somewhat “home-brewed” insulin, but there would still be several costly regulatory hurdles for each product. Even if crowdfunding could support these “biohacked” insulin barriers, would the resulting product be the best treatment for all patients? Would it still result in a high-cost product?

Historically, the US Food and Drug Administration (FDA) has regulated insulins as small molecule drugs; thus, the few generics available are actually branded competitors and considered “follow-on” insulins. The FDA has announced insulins will be transitioned from the small molecule pathway to the biologics pathway effective in March 2020 as part of their Biosimilars Action Plan. According to acting FDA Commissioner, Dr. Ned Sharpless, after this transition, the FDA will be able to license biosimilar and interchangeable insulin products that may be substituted at the pharmacy, potentially leading to increased access and lower costs for patients.

While the idea for “generic” (cheaper) insulin is becoming more of a reality, what will patients do in the meantime for a disease state in which the treatment is not optional? Will interchangeable biosimilar insulin finally be the solution for reversing the constant upward trajectory of insulin prices?

Share on FacebookShare on TwitterShare on Linkedin
Tags: Magellan, Magellan Health, Magellan RX, Magellan Rx Management, Medical Pharmacy
Lara Frick
Lara Frick
Lara Frick, PharmD, BCPS, BCPP joined Magellan Rx Management as a Drug Information Clinical Pharmacist in 2015. In this role, she serves as a drug information resource across Magellan, evaluating new drugs, developing clinical policies, evaluating therapeutic class reviews, and researching and creating content for clinical publications. Since obtaining her Doctor of Pharmacy degree and completing her pharmacy practice residency, she has earned over a decade of expertise in clinical management, formulary development, and drug intelligence in the academic, acute care, mental health, and outpatient settings. As an advocate for evidence-based practice, she collaborates with a wide variety of clientele, including direct patient care and commercial, Medicaid, and Medicare plans.
Previous post Caring for Yourself after an Organ Transplant Next post Going Beyond Traditional Benefits: Healthcare Systems Begin to Address Social Determinants of Health

Related Articles

You’ve prescribed an opioid: Now what? 5 key strategies to prevent addiction

You’ve prescribed an opioid: Now what? 5 key strategies to prevent addiction

by Caroline Carney, MD
February 26, 2018
Grief and Loss

Loss and Grief during the Pandemic

by Steven E. Pratt, MD
January 12, 2021
In 2012, the Centers for Disease Control (CDC) calculated that healthcare providers wrote 259 million prescriptions for opioid painkillers. That is enough for every American adult to receive a bottle of pills.

Medicine Cabinet Minefield: How old prescriptions drugs are fueling an opioid addiction crisis

by Magellan Health Insights
November 7, 2016

1 comment. Leave new

Traditional Drug to Biologic: A Change 10 Years in the Making
June 22, 2020 10:16 PM

[…] described in a previous blog post, the cost of insulin has risen substantially, leading patients to take desperate measures. At a […]

Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Magellan Health Logo

To learn more about how Magellan can support your organization, please visit MagellanHealth.com.

Topic suggestions or questions?
Send us your ideas at

Connect with us:

Trending Topics

  • A Present Day Look at PTSD
  • Medicine Cabinet Minefield: How old prescriptions drugs are fueling an opioid addiction crisis
  • The Trends and Complexities of Provider-Administered Drugs

Categories

Stay in the Know

Get the latest news and trending insights sent straight to your inbox.


HomeAboutResourcesVoicesContact
© 1999-2016 Magellan Health, Inc. All Rights Reserved.